These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32594788)

  • 1. Comparison of survival distributions in clinical trials: A practical guidance.
    Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
    Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
    Royston P; B Parmar MK
    Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size calculation for the combination test under nonproportional hazards.
    Cheng H; He J
    Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved logrank-type tests for survival data using adaptive weights.
    Yang S; Prentice R
    Biometrics; 2010 Mar; 66(1):30-8. PubMed ID: 19397582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves.
    Uno H; Tian L; Claggett B; Wei LJ
    Stat Med; 2015 Dec; 34(28):3680-95. PubMed ID: 26194988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials.
    Garès V; Andrieu S; Dupuy JF; Savy N
    Stat Med; 2015 Feb; 34(4):541-57. PubMed ID: 25388274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
    JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
    Yang S
    Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous use of weighted logrank and standardized Kaplan-Meier statistics.
    Yang P; Fleming TR
    J Biopharm Stat; 2006; 16(2):241-52. PubMed ID: 16584070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.
    Horiguchi M; Cronin AM; Takeuchi M; Uno H
    Stat Med; 2018 Jul; 37(15):2307-2320. PubMed ID: 29682762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group sequential methods based on supremum logrank statistics under proportional and nonproportional hazards.
    Boher JM; Filleron T; Sfumato P; Bunouf P; Cook RJ
    Stat Methods Med Res; 2024 Jul; 33(7):1137-1151. PubMed ID: 38840446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
    Rauch G; Brannath W; Brückner M; Kieser M
    Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A method for sequential analysis of survival data with nonproportional hazards.
    Sooriyarachchi MR; Whitehead J
    Biometrics; 1998 Sep; 54(3):1072-84. PubMed ID: 9750253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modestly weighted logrank tests.
    Magirr D; Burman CF
    Stat Med; 2019 Sep; 38(20):3782-3790. PubMed ID: 31131462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
    Phadnis MA; Wetmore JB; Mayo MS
    Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.
    Yung G; Liu Y
    Biometrics; 2020 Sep; 76(3):939-950. PubMed ID: 31797363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.